Trial
NCT04330625
Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Duke University
Collaborators
—
Condition
Hyperglycemia Drug Induced
Intervention
REMD-477
Why stopped
Lack of enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-08